312 related articles for article (PubMed ID: 25840583)
1. CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.
Chen R; Hou J; Newman E; Kim Y; Donohue C; Liu X; Thomas SH; Forman SJ; Kane SE
Mol Cancer Ther; 2015 Jun; 14(6):1376-84. PubMed ID: 25840583
[TBL] [Abstract][Full Text] [Related]
2. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
[TBL] [Abstract][Full Text] [Related]
3. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.
Bhatt S; Ashlock BM; Natkunam Y; Sujoy V; Chapman JR; Ramos JC; Mesri EA; Lossos IS
Blood; 2013 Aug; 122(7):1233-42. PubMed ID: 23838350
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Vaklavas C; Forero-Torres A
Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
[TBL] [Abstract][Full Text] [Related]
5. A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.
Kim SJ; Do YR; Lee HS; Lee WS; Kong JH; Kwak JY; Eom HS; Moon JH; Yi JH; Lee JO; Jo JC; Yang DH
Blood Res; 2023 Dec; 58(4):194-200. PubMed ID: 38031473
[TBL] [Abstract][Full Text] [Related]
6. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity.
Heiser RA; Cao AT; Zeng W; Ulrich M; Younan P; Anderson ME; Trueblood ES; Jonas M; Thurman R; Law CL; Gardai SJ
Mol Cancer Ther; 2024 Jan; 23(1):68-83. PubMed ID: 37775098
[TBL] [Abstract][Full Text] [Related]
8. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma.
Mei M; Tsai NC; Palmer J; Armenian S; Chen R; Rosen S; Forman S; Popplewell L; Kwak L; Martin P; Maddocks K; Bond D; Herrera AF
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38693037
[TBL] [Abstract][Full Text] [Related]
10. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.
Noguchi K; Ikawa Y
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas.
Ribereau-Gayon E; Donzel M; Pham F; Romain-Scelle N; Perier-Muzet M; Balme B; Traverse-Glehen A; Ghesquières H; Dalle S
Leuk Lymphoma; 2023; 64(8):1424-1432. PubMed ID: 37255021
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real-world study.
Zhang X; Qiao H; Chai X; Gao X; Ma R; Li Y; Zhu Z; Zhang M
Cancer Med; 2023 Dec; 12(24):21725-21734. PubMed ID: 37975251
[TBL] [Abstract][Full Text] [Related]
13. Successful Pregnancy and Fetal Outcomes Following Brentuximab Vedotin for Early Relapsed Classic Hodgkin Lymphoma After Autologous Stem Cell Transplant.
Goto A; Fujita C; Horiguchi H; Iyama S; Kobune M
Cureus; 2024 Mar; 16(3):e57291. PubMed ID: 38690456
[TBL] [Abstract][Full Text] [Related]
14. The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
Grover NS; Dittus C; Thakkar A; Beaven AW
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):510-518. PubMed ID: 38066906
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.
Heidegger S; Beer AJ; Geissinger E; Rosenwald A; Peschel C; Ringshausen I; Keller U
Onco Targets Ther; 2014; 7():1123-7. PubMed ID: 25018638
[TBL] [Abstract][Full Text] [Related]
16. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.
Marques-Piubelli ML; Kim DH; Medeiros LJ; Lu W; Khan K; Gomez-Bolanos LI; Rodriguez S; Parra ER; Ok CY; Aradhya A; Solis LM; Nieto YL; Steiner R; Ahmed S; Vega F
Histopathology; 2023 Jul; 83(1):143-148. PubMed ID: 36994939
[TBL] [Abstract][Full Text] [Related]
17. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of minimal residual disease for monitoring of paediatric patients with relapsed/refractory anaplastic large-cell lymphoma treated with brentuximab vedotin: A case series.
Contarini G; Carraro E; Lovisa F; Martire G; Lo Nigro L; Sala A; Pillon M; Mussolin L
Br J Haematol; 2024 Jan; 204(1):352-355. PubMed ID: 37822050
[No Abstract] [Full Text] [Related]
19. In Doxorubicin-Adapted Hodgkin Lymphoma Cells, Acquiring Multidrug Resistance and Improved Immunosuppressive Abilities, Doxorubicin Activity Was Enhanced by Chloroquine and GW4869.
Casagrande N; Borghese C; Avanzo M; Aldinucci D
Cells; 2023 Nov; 12(23):. PubMed ID: 38067159
[TBL] [Abstract][Full Text] [Related]
20. Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.
Prokoph N; Larose H; Lim MS; Burke GAA; Turner SD
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29601554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
